Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on October 5, 2005
J Am Soc Nephrol 16: 3149-3150, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005090934

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005090934v1
16/11/3149    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warnock, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warnock, D. G.

Editorials

Towards a Definition and Classification of Acute Kidney Injury

David G. Warnock

Nephrology Research and Training Center, Departments of Medicine and Physiology, University of Alabama at Birmingham, Alabama

Address correspondence to: Dr. David G. Warnock, Room 647 THT, 1530 3rd Avenue South, UAB Station, Birmingham, AL 35294-0006. Phone: 205-934-3585; Fax: 205-934-1879; dwarnock{at}uab.edu

Chertow and colleagues (1) have an interesting and provocative paper in this issue of JASN that brings a pragmatic approach to bear on the issue of defining acute renal failure. This area is rapidly gaining prominence and was the theme of one of the American Society of Nephrology’s research focus groups last spring. In that meeting, the terminology "acute kidney injury" (AKI) was put forth as the preferred nomenclature for the clinical disorder that we are all familiar with, with the understanding that its spectrum is broader than the subset of patients who find themselves in an intensive care unit with an acute need for dialysis support.

The issues of nomenclature, classification, and assessment of severity have long been recognized as problematic, and they were one of the foci of a National Institutes of Health consensus conference on acute renal failure nearly 10 yr ago (2); progress on these issues has been rather modest in the interval. The critical care community has been active, and representatives from nephrology and critical care medicine have developed a working group called the Acute Dialysis Quality Initiative (3,4). The efforts of this group have been focused on the issues involved with intensive and critical care, and a classification proposal has been developed that is based on physiologic measurements including serum creatinine and urine output (5,6).

The fact that the mortality with AKI injury in the intensive care setting can be extraordinarily high and that AKI is often accompanied by multiple organ failure underlies the importance of making significant progress in this area. In the most recent survey, the prevalence of severe AKI in the intensive care setting that required some form of renal replacement therapy approached 6%, with an in-patient mortality rate of 60.3% (7). A number of clinical trials have been carried out in AKI, but with the exception of a select few that focused on contrast nephropathy, the results have not been very encouraging. A common issue for all such studies is a workable definition of what constitutes AKI, with the realization that the more severe the injury, the more likely the overall outcome will be unfavorable. On the other hand, if the threshold is set too low, the concern has been that minor, clinically insignificant changes in kidney function will be included so that any imposed intervention will not affect overall outcome.

This is the context in which the paper by Chertow et al. (1) makes its contribution. Based on a survey of >19,000 hospital admissions, a subset of patients were selected for whom the clinical caregivers had obtained more than one serum creatinine determination. The analysis considered both the absolute and fractional increase in serum creatinine, and evaluated mortality, length of stay, and other outcome measures associated with the changes in serum creatinine. This approach can be criticized because there may have been an ascertainment bias (e.g., Why was more than one creatinine ordered?), measurements of urine output (e.g., oliguric versus nonoliguric or even anuric AKI) were not available, and the baseline kidney function for these admitted patients was not known.

Despite these shortcomings, which are inherent in the design of a large-scale surveillance study, the results presented by Chertow et al. are well worth considering. When outcome was simply defined as death, there was a graded impact on outcome that clearly reflected the severity of AKI (see Table 2 in the authors’ article [1].). Even with only a modest 0.3 mg/dl increase in the serum creatinine level, there was a 4.1-fold risk of mortality. The increased relative risk was still present when the association was adjusted for age, and disease severity. Some would be inclined to reject a modest 0.3 mg/dl increase in serum creatinine as "clinically insignificant" or explainable by prerenal issues, but the fact that the relative risk of a poor outcome increased as the severity of injury increased, judged by the magnitude of the creatinine increases, argues that the predictive power of even a modest change in serum creatinine should not be ignored.

Chronic kidney disease (CKD) has been defined by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines with stages based on estimates of the GFR (8). This process has been rigorous, and clinical action plans have been developed for each stage. The impact of this approach has been impressive, and the stages of CKD are now codified in the next iteration of the International Classification of Disease, Ninth Revision (ICD-9) codes that will be published in October 2005. Of note, the risk for overall outcomes, including death, cardiovascular events, and even number of hospital days are related to the severity of CKD, with the first increase apparent in stage 3 CKD (9). The similarity of this finding, also published by Chertow and colleagues (9), to the graded degree of risk reported in the current paper for AKI (1) lends strong support for developing a coherent definition and terminology for AKI, and for discerning some measure of the severity of the injury, insofar as that can be related to outcomes in an analogous manner to what has been so successful for CKD.

The skeptic is still bothered that such a "trivial" increase of serum creatinine can have anything to do with actual kidney injury. If one remembers the basic physiology of creatinine clearance, there are both filtration and secretory components (10). Modest changes in serum creatinine may not reflect changes in filtration, but could reflect subtle derangements in the plasma-flow–dependent component of active creatinine secretion by the organic ion transport systems in the proximal tubule (11,12). From this perspective, serum creatinine becomes more than a marker for glomerular filtration—it can then be viewed as a biomarker for acute tubular injury. Other biomarkers, such as cystatin C (13), KIM-1 (14), and neutrophil gelatinase–associated lipocalin (15) are also being actively investigated as biomarkers of AKI. The role of reactive oxygen molecules is surely important, and an improved understanding of the role of inflammation has suggested, targeting strategies for this aspect of AKI (16). If subtle changes in biomarkers for acute cellular injury can be validated as predicting overall outcome in patients with AKI, then the field will have taken a major step forward (14). This approach may well provide new avenues for designing intervention studies that could actually affect the outcomes for patients with AKI.


    Footnotes
 
Published online ahead of print. Publication date available at www.jasn.org.

See related article, "Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients," on pages 3365–3371


    References
 Top
 References
 

  1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Neph 16 : 3365 –3371, 2005
  2. DuBose TD Jr, Warnock DG, Mehta RL, Bonventre JV, Hammerman MR, Molitoris BA, Paller MS, Siegel NJ, Scherbenske J, Striker GE: Acute renal failure in the 21st century: Recommendations for management and outcomes assessment. Am J Kidney Dis 29 : 793 –799, 1997[Medline]
  3. Kellum JA, Bellomo R, Ronco C, Mehta R, Clark W, Levin NW: The 3rd International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Int J Artif Organs 28 : 441 –444, 2005[Medline]
  4. Kellum JA, Mehta RL, Ronco C: Acute dialysis quality initiative (ADQI). Contrib Nephrol 132 : 258 –265, 2001
  5. Bellomo R, Kellum JA, Ronco C: Defining acute renal failure: Physiological principles. Intensive Care Med 30 : 33 –37, 2004[CrossRef][Medline]
  6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure—Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 : R204 –R212, 2004[CrossRef][Medline]
  7. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 294 : 813 –818, 2005[Abstract/Free Full Text]
  8. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 : S1 –S266, 2002[CrossRef][Medline]
  9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296 –1305, 2004[Abstract/Free Full Text]
  10. Serdar MA, Kurt I, Ozcelik F, Urhan M, Ilgan S, Yenicesu M, Kenar L, Kutluay T: A practical approach to glomerular filtration rate measurements: Creatinine clearance estimation using cimetidine. Ann Clin Lab Sci 31 : 265 –273, 2001[Abstract/Free Full Text]
  11. Urakami Y, Kimura N, Okuda M, Inui K: Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 21 : 976 –981, 2004[CrossRef][Medline]
  12. Urakami Y, Kimura N, Okuda M, Masuda S, Katsura T, Inui K: Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab Pharmacokinet 20 : 200 –205, 2005[Medline]
  13. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A: Early detection of acute renal failure by serum cystatin C. Kidney Int 66 : 1115 –1122, 2004[CrossRef][Medline]
  14. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62 : 237 –244, 2002[CrossRef][Medline]
  15. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 : 1231 –1238, 2005[CrossRef][Medline]
  16. Devarajan P: Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 17 : 193 –199, 2005[CrossRef][Medline]



This article has been cited by other articles:


Home page
CJASNHome page
W. Van Biesen, R. Vanholder, and N. Lameire
Defining Acute Renal Failure: RIFLE and Beyond
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1314 - 1319.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P. Devarajan
Update on Mechanisms of Ischemic Acute Kidney Injury
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1503 - 1520.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005090934v1
16/11/3149    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warnock, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warnock, D. G.


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP